Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

Biotech major Amgen Inc AMGN presented detailed results from the phase III cardiovascular outcomes study FOURIER on its PCSK9 inhibitor Repatha at the 2017 American College of Cardiology conference Top line results from the study were announced last month Data presented showed